309 related articles for article (PubMed ID: 16513839)
21. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
22. Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer.
Glinsky GV; Krones-Herzig A; Glinskii AB; Gebauer G
Mol Carcinog; 2003 Aug; 37(4):209-21. PubMed ID: 12891630
[TBL] [Abstract][Full Text] [Related]
23. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.
Lin DW; Coleman IM; Hawley S; Huang CY; Dumpit R; Gifford D; Kezele P; Hung H; Knudsen BS; Kristal AR; Nelson PS
J Clin Oncol; 2006 Aug; 24(23):3763-70. PubMed ID: 16822846
[TBL] [Abstract][Full Text] [Related]
24. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
25. Pan-cadherin as a high level phenotypic biomarker for prostate cancer.
Wehbi NK; Dugger AL; Bonner RB; Pitha JV; Hurst RE; Hemstreet GP
J Urol; 2002 May; 167(5):2215-21. PubMed ID: 11956481
[TBL] [Abstract][Full Text] [Related]
26. Identification of prognostic biomarkers for prostate cancer.
Kosari F; Munz JM; Savci-Heijink CD; Spiro C; Klee EW; Kube DM; Tillmans L; Slezak J; Karnes RJ; Cheville JC; Vasmatzis G
Clin Cancer Res; 2008 Mar; 14(6):1734-43. PubMed ID: 18347174
[TBL] [Abstract][Full Text] [Related]
27. Association between integrin expression and prognosis in localized prostate cancer.
Pontes-Júnior J; Reis ST; de Oliveira LC; Sant'anna AC; Dall'oglio MF; Antunes AA; Ribeiro-Filho LA; Carvalho PA; Cury J; Srougi M; Leite KR
Prostate; 2010 Aug; 70(11):1189-95. PubMed ID: 20564421
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
29. High expression of a new marker PCA-1 in human prostate carcinoma.
Konishi N; Nakamura M; Ishida E; Shimada K; Mitsui E; Yoshikawa R; Yamamoto H; Tsujikawa K
Clin Cancer Res; 2005 Jul; 11(14):5090-7. PubMed ID: 16033822
[TBL] [Abstract][Full Text] [Related]
30. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis.
Peehl DM; Shinghal R; Nonn L; Seto E; Krishnan AV; Brooks JD; Feldman D
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):131-41. PubMed ID: 15555907
[TBL] [Abstract][Full Text] [Related]
31. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
33. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.
Reyes I; Tiwari R; Geliebter J; Reyes N
Biomedica; 2007 Jun; 27(2):190-203. PubMed ID: 17713630
[TBL] [Abstract][Full Text] [Related]
34. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
35. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
36. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
[TBL] [Abstract][Full Text] [Related]
37. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
Lapointe J; Li C; Giacomini CP; Salari K; Huang S; Wang P; Ferrari M; Hernandez-Boussard T; Brooks JD; Pollack JR
Cancer Res; 2007 Sep; 67(18):8504-10. PubMed ID: 17875689
[TBL] [Abstract][Full Text] [Related]
38. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens.
Bright RK; Vocke CD; Emmert-Buck MR; Duray PH; Solomon D; Fetsch P; Rhim JS; Linehan WM; Topalian SL
Cancer Res; 1997 Mar; 57(5):995-1002. PubMed ID: 9041206
[TBL] [Abstract][Full Text] [Related]
39. A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation.
Daly-Burns B; Alam TN; Mackay A; Clark J; Shepherd CJ; Rizzo S; Tatoud R; O'Hare MJ; Masters JR; Hudson DL
Differentiation; 2007 Jan; 75(1):35-48. PubMed ID: 17244020
[TBL] [Abstract][Full Text] [Related]
40. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
